FRANKLIN LAKES, N.J.,
Sept. 16, 2016 /PRNewswire/
-- BD (Becton, Dickinson and Company) (NYSE: BDX) and Vancive
Medical Technologies™, an Avery
Dennison (NYSE: AVY) business, today launched a line of
transparent vascular dressings with chlorhexidine gluconate (CHG)
antimicrobial preservative that are designed to enhance patient
care and be easy for clinicians to apply and remove.
The new BD ChloraShield™ dressings, which feature BeneHold™ CHG,
an innovative adhesive technology from Vancive Medical
Technologies, comfortably secure the dressing to the skin, absorb
fluids and protect the site from external contaminants. The CHG
incorporated within the adhesive preserves the dressing from
microbial growth, making them well-suited for catheter insertion
sites. The Infusion Nurses Society recently released guidelines
recommending the use of CHG dressings.1 BD is the
exclusive distributor of the dressings worldwide.
"The combination of vascular access expertise from BD, infection
prevention expertise from the CareFusion acquisition and CHG
adhesive technology from Vancive Medical Technologies creates a
powerful combination for a new vascular access product," said
Stephen Hartley, global vice
president of Infection Prevention for BD. "The new ChloraShield IV
dressings complete BD's portfolio to offer a comprehensive set of
products for vascular access procedures, including skin prep,
catheters, connectors and flush products."
BD ChloraShield dressings are available in a variety of designs
including bordered and non-bordered as well as sizes commonly used
for peripheral IVs and PICCs.
"BeneHold CHG adhesive technology is well-suited for vascular
access dressings," said Kirsten
Newquist general manager for Vancive Medical Technologies.
"The collaboration with BD brings together complementary expertise
from both companies and we look forward to expanding the product
offerings in the future."
BD and Vancive Medical Technologies will showcase the new BD
ChloraShield dressings in booth #423 at the 30th annual
Association for Vascular Access Conference, being held Sept. 16-19 in Orlando,
Fla. To learn more about ChloraShield IV dressings with CHG
antimicrobial visit, www.bd.com/ChloraShieldIV.
About BD
BD is a global medical technology company
that is advancing the world of health by improving medical
discovery, diagnostics and the delivery of care. BD leads in
patient and health care worker safety and the technologies that
enable medical research and clinical laboratories. The company
provides innovative solutions that help advance medical research
and genomics, enhance the diagnosis of infectious disease and
cancer, improve medication management, promote infection
prevention, equip surgical and interventional procedures, optimize
respiratory care and support the management of diabetes. The
company partners with organizations around the world to address
some of the most challenging global health issues. BD has more than
45,000 associates across 50 countries who work in close
collaboration with customers and partners to help enhance outcomes,
lower health care delivery costs, increase efficiencies, improve
health care safety and expand access to health. For more
information on BD, please visit bd.com.
About Vancive Medical Technologies
Vancive Medical
Technologies is a medical technology company with more than three
decades of expertise in adhesive chemistries and material
technologies for medical applications using pressure sensitive
adhesives. The company's applications and technologies are an
integral part of products that are in daily use in medical
facilities throughout the world. Through long-term relationships
with original equipment manufacturers, industry-specific converters
and leading universities, Vancive Medical Technologies continually
finds new ways to develop products that can improve patient care.
Vancive Medical Technologies is an Avery
Dennison business headquartered in Chicago, Illinois. To learn more about Vancive
Medical Technologies, visit www.vancive.averydennison.com.
About Avery
Dennison
Avery
Dennison (NYSE:AVY) is a global leader in labeling and
packaging materials and solutions. The company's applications and
technologies are an integral part of products used in every major
market and industry. With operations in more than 50 countries and
more than 25,000 employees worldwide, Avery
Dennison serves customers with insights and innovations that
help make brands more inspiring and the world more intelligent.
Headquartered in Glendale,
California, the company reported sales of $6 billion in 2015. Learn more at
www.averydennison.com.
1Journal of Infusion Nursing, Volume 39, pgs. S82-83,
January/February 2016.
BD
Contacts:
|
Vancive
Contacts:
|
|
|
Troy
Kirkpatrick
|
Andrew
Deckert
|
BD Public
Relations
|
Global Marketing Communications
Manager
|
858.617.2361
|
+1 224 374
2109
|
troy.kirkpatrick@bd.com
|
andrew.deckert@averydennison.com
|
|
|
Monique N.
Dolecki
BD Investor
Relations
201.847.5378
monique_dolecki@bd.com
|
Barbara Van
Rymenam
Global Director, CHG
Program
+32 (0)497
103233
barbara.van.rymenam@eu.averydennison.com
|
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/bd-and-vancive-medical-technologies-launch-new-vascular-dressings-with-chg-antimicrobial-300329206.html
SOURCE BD (Becton, Dickinson and Company)